What it's for (Indications)
- Ivermectin is an antiparasitic medication primarily indicated for the treatment of specific parasitic infections.
- It is approved for the treatment of intestinal strongyloidiasis (due to *Strongyloides stercoralis*) and onchocerciasis (river blindness, due to *Onchocerca volvulus*).
- In addition to these primary indications, topical formulations are used for pediculosis capitis (head lice) and cutaneous scabies.
- Oral ivermectin is also used off-label for the treatment of scabies and certain other helminthic infections, typically when other treatments are ineffective or contraindicated.
- Its efficacy is specific to parasites and it is not indicated for viral, bacterial, or fungal infections.
- The use of ivermectin should always be based on confirmed parasitic diagnosis or a strong clinical suspicion in endemic areas.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of ivermectin is highly individualized and depends on the specific parasitic infection being treated, the patient's body weight, and the formulation (oral or topical). For oral strongyloidiasis and onchocerciasis, a single dose of 200 micrograms per kilogram of body weight is typically administered. In cases of onchocerciasis, retreatment may be necessary every 3 to 12 months depending on microfilarial density and re-exposure risk. For scabies, an oral dose of 200 micrograms per kilogram, repeated in 7 to 14 days, is commonly used. Topical formulations for pediculosis or scabies have their own specific application instructions regarding quantity and duration, which must be followed precisely. It is crucial to strictly adhere to the prescribed dosage and regimen provided by a healthcare professional, as incorrect dosing can lead to treatment failure, increased risk of adverse effects, or potential toxicity. |
Safety & Warnings
Common Side Effects
- Ivermectin treatment can be associated with a range of side effects, which vary in severity and frequency.
- Common adverse reactions include dizziness, nausea, vomiting, diarrhea, abdominal pain, fatigue (asthenia), somnolence, vertigo, and tremor.
- In patients treated for onchocerciasis, a Mazzotti reaction can occur, characterized by fever, headache, dizziness, arthralgia, myalgia, facial and peripheral edema, rash, pruritus, conjunctivitis, lymphadenitis, and ocular symptoms, resulting from the immunological response to dying microfilariae.
- Other less common but potentially serious side effects include orthostatic hypotension, hepatic abnormalities (e.
- g.
- , transient elevations in liver enzymes), and neurological events such as seizures, particularly in individuals with compromised blood-brain barrier integrity or co-infection with *Loa loa*.
- Patients should report any unusual or severe symptoms to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: **SERIOUS WARNINGS: POTENTIAL FOR SEVERE NEUROLOGICAL ADVERSE EVENTS IN LOA LOA CO-INFECTION AND INAPPROPRIATE USE** Ivermectin does not currently carry a formal FDA Black Box Warning. However, healthcare providers must be acutely aware of significant safety concerns. Patients in *Loa loa*-endemic areas, especially those with high microfilarial loads, are at substantial risk of developing severe, potentially fatal, neurological adverse reactions, including encephalopathy and coma, following ivermectin administration. Thorough pre-treatment screening for *Loa loa* infection is imperative in these populations to mitigate this risk. Furthermore, ivermectin is an antiparasitic agent and is **not indicated for the treatment or prevention of viral infections, including COVID-19**. Inappropriate off-label use for non-approved indications can lead to serious adverse effects, drug interactions, delay or substitution of proven medical therapies, and contribute to public health risks and drug resistance. Patients should only use ivermectin under the direct supervision and prescription of a qualified healthcare professional, strictly adhering to approved indications and dosages.
- Ivermectin requires careful administration due to several important warnings.
- A significant concern, especially in areas endemic for onchocerciasis and loiasis, is the risk of severe neurological adverse reactions, including encephalopathy and even death, in patients co-infected with high microfilarial loads of *Loa loa*.
- Pre-treatment screening for *Loa loa* infection is highly recommended in such regions.
- Patients treated for onchocerciasis should be monitored for Mazzotti reactions, which can be severe and require symptomatic management.
- Ivermectin is not indicated for viral or bacterial infections, and its off-label use for such conditions can delay appropriate medical care, contribute to adverse outcomes, and potentially lead to drug shortages for approved indications.
- Caution is advised in patients with liver impairment, as the drug is extensively metabolized hepatically.
- Pediatric patients weighing less than 15 kg are generally not recommended for oral ivermectin treatment due to limited safety data.
How it Works (Mechanism of Action)
Ivermectin belongs to the avermectin class of antiparasitic agents. Its primary mechanism of action involves selectively and with high affinity binding to glutamate-gated chloride ion channels, which are abundant in the nerve and muscle cells of invertebrates but are not present in mammals. This binding leads to an increase in the permeability of the parasite's cell membrane to chloride ions. The subsequent influx of chloride ions causes hyperpolarization of the cell membrane, resulting in paralysis and ultimately death of the parasite. While ivermectin also has affinity for other ligand-gated chloride channels, such as those mediated by gamma-aminobutyric acid (GABA), its primary therapeutic effect in helminths is attributed to the glutamate-gated channels. In mammals, these channels are largely confined to the central nervous system, and ivermectin does not readily cross the intact blood-brain barrier at therapeutic doses, contributing to its relative safety profile in humans. However, at higher doses or in individuals with a compromised blood-brain barrier, neurological effects can occur.